Patent ID: 9023793
Filing Date: 2015-05-05
Classification: A61K,A61P

Abstract:
1. A pharmaceutical formulation for intranasal delivery of carbetocin, comprising: a) carbetocin in a concentration of from about 1.5 mg/ml to about 10 mg/ml; b) methyl-β-cyclodextrin in a concentration of from about 10 mg/ml to about 40 mg/ml; c) EDTA in a concentration of from about 2 mg/ml to about 5 mg/ml; d) sodium chloride in a concentration of from about 40 mM to about 70 mM; e) arginine, or a salt thereof, in a concentration of about 10 mM; f) acetate in a concentration of about 10 mM; and g) chlorobutanol in a concentration of from about 2.5 mg/ml to about 5 mg/ml, wherein the formulation has a pH from about 4 to about 6.